Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of $2.16 billion. The enterprise value is $2.21 billion.
Important Dates
The last earnings date was Tuesday, March 31, 2026, after market close.
| Earnings Date | Mar 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 48.39 million shares outstanding. The number of shares has increased by 1.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 48.39M |
| Shares Change (YoY) | +1.17% |
| Shares Change (QoQ) | +1.69% |
| Owned by Insiders (%) | 3.28% |
| Owned by Institutions (%) | 13.99% |
| Float | 31.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 544.64 |
| PS Ratio | 56.54 |
| Forward PS | 18.22 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 57.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09
| Current Ratio | 1.09 |
| Quick Ratio | 1.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.05 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.06% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -106.13% |
| Weighted Average Cost of Capital (WACC) | 7.49% |
| Revenue Per Employee | $382,682 |
| Profits Per Employee | -$281,331 |
| Employee Count | 100 |
| Asset Turnover | 0.48 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Nanobiotix has paid $3,522 in taxes.
| Income Tax | 3,522 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1,096.89% in the last 52 weeks. The beta is 0.58, so Nanobiotix's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +1,096.89% |
| 50-Day Moving Average | 35.50 |
| 200-Day Moving Average | 23.42 |
| Relative Strength Index (RSI) | 57.25 |
| Average Volume (20 Days) | 97,000 |
Short Selling Information
The latest short interest is 37,392, so 0.08% of the outstanding shares have been sold short.
| Short Interest | 37,392 |
| Short Previous Month | 11,234 |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 0.51 |
Income Statement
In the last 12 months, Nanobiotix had revenue of $38.27 million and -$28.13 million in losses. Loss per share was -$0.59.
| Revenue | 38.27M |
| Gross Profit | 38.27M |
| Operating Income | -12.78M |
| Pretax Income | -28.13M |
| Net Income | -28.13M |
| EBITDA | -12.32M |
| EBIT | -12.78M |
| Loss Per Share | -$0.59 |
Full Income StatementBalance Sheet
The company has $61.93 million in cash and $111.92 million in debt, with a net cash position of -$49.98 million or -$1.03 per share.
| Cash & Cash Equivalents | 61.93M |
| Total Debt | 111.92M |
| Net Cash | -49.98M |
| Net Cash Per Share | -$1.03 |
| Equity (Book Value) | -99.19M |
| Book Value Per Share | -2.05 |
| Working Capital | 6.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$39.24 million and capital expenditures -$631,678, giving a free cash flow of -$39.42 million.
| Operating Cash Flow | -39.24M |
| Capital Expenditures | -631,678 |
| Depreciation & Amortization | 456,164 |
| Net Borrowing | 44.33M |
| Free Cash Flow | -39.42M |
| FCF Per Share | -$0.81 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -33.39% and -73.52%.
| Gross Margin | 100.00% |
| Operating Margin | -33.39% |
| Pretax Margin | -73.51% |
| Profit Margin | -73.52% |
| EBITDA Margin | -32.18% |
| EBIT Margin | -33.39% |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.17% |
| Shareholder Yield | -1.17% |
| Earnings Yield | -1.30% |
| FCF Yield | -1.82% |
Analyst Forecast
The average price target for Nanobiotix is $33.74, which is -26.97% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $33.74 |
| Price Target Difference | -26.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 43.89% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of 1.11 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.11 |
| Piotroski F-Score | 1 |
